Keywords: strong, earnings, growth, bristol-myers, squibb, pravachol, sales
Strong earnings growth for Bristol-Myers Squibb but Pravachol sales slip 5%
Article | 25 April 2000
Bristol-Myers Squibb has reported a net income rise of 15% to $1.22billion for first-quarter 2000 on turnover of $5.26 billion, an increase of 8%. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
